Consultation
Pharmaceutical and Healthcare Consultation Services in the MENA
PROMO PHARMA supports healthcare and pharmaceutical companies in these fields:
- Market research, market analysis and sales data analysis
- Market access, pricing and reimbursement
- Business brokerage
- Medical affairs with the Saudi FDA (SFDA), for example MDEL, MDNR, MDIL, MDMA, e-Cosma and import licenses
- Supportive materials such as product knowledge, training, e-details and medical brochures
- Market intelligence, creative intelligence and sales analysis
- Mystery shopping and customer satisfaction measurement
Market access and market research
Market research, market analysis and market access for Egypt and the MENA
We turn audited sales data into decisions. Our market research and market analysis show how a product class is moving, who prescribes it and where the gaps are. Our market access work prepares the evidence for pricing, reimbursement and formulary placement. Two ready-made opportunity assessments for the Egyptian market are available now, and we run custom studies for other products and countries.
GLP-1 receptor agonists in the Egyptian market
Opportunity assessment based on audited Egyptian market sales for MAT 2021 to 2025, with product rankings to December 2025 and year-to-date figures to April 2026. The class grew from about EGP 144 million in 2021 to about EGP 3.26 billion by December 2025. Opportunity score: 88 out of 100.
Colchicine in Egypt: a forgotten generic at three crossroads
Market research report based on audited sales data from 2021 to 2025. The market is about EGP 118 million for the year to December 2025, up from about EGP 65 million in 2021. It covers gout, familial Mediterranean fever and cardiovascular repositioning. Opportunity score: 58 out of 100.
BUSINESS BROKERAGE
We connect brand owners and manufacturers worldwide with suitable distributors in the MENA region, so they can build a secure business there. We are always looking for new brands and agencies for the healthcare and pharmaceutical markets of the GCC and the Middle East.
PRIVATE LABELING
Private labeling (or OEM) turns generic or customized pharmaceutical products into marketable items that compete with national brands. Intermediary companies and retailers that buy from wholesalers can re-brand and personalize these products, and they often sell them at a discount to branded products.
We know every business is different. We support companies of all sizes with product development and manufacturing needs, from concept to shelf, at any stage or scale.
We help you choose the right formulations and packaging and build the product ranges you need. Our innovation team works with you on formulations and delivery formats. Our regulatory team checks compliance in your chosen distribution country, and manufacturing, analytical and packaging teams prepare the product for market.
MYSTERY SHOPPING
We help pharmacies and clinics measure patient and customer satisfaction after a clinic or pharmacy visit. We also assess the user experience and interface (UX/UI) and the customer service of e-shops. The survey method is chosen to fit your objective, for B2C and B2B, and includes mystery shops, phone calls, online chat, email, audio mystery shopping, incentive shops, integrity shopping and KPI audits.
IDEA INSPIRATION
We give you access to an archive of medical communication tools, concepts, visual aids and TV commercials from pharmaceutical and healthcare products worldwide. See our creative services.
SUCCESS STORY
On 17 October 2017, PROMO PHARMA and its regulatory affairs team cleared the HAL robotic device for use in Saudi Arabia, after a long and exacting process under Saudi FDA regulations. It was one of our most significant regulatory projects: the registration of a new class of robotic medical device.
HAL is a Japanese robotic device for people with lower-limb disorders and weakening legs. It is available exclusively at Abdul Latif Jameel (ALJ) Hospital in Jeddah, Saudi Arabia.
CYBERDYNE announced the export of eight units of Medical HAL to Saudi Arabia, following the Saudi Food and Drug Authority (SFDA) medical device approval in August 2017. These are the first units for Cybernic Treatment in Saudi Arabia. ALJ Hospital, owned by CYBERDYNE’s business partner Abdul Latif Jameel, provides the treatment.
The Japanese government representative presented the project as an example of the Japanese medicine and healthcare industry’s contribution to Saudi Arabia under “Saudi Japan Vision 2030”, at the Saudi Arabia-Japan Business Council Meeting on 9 October 2017 in Riyadh.
Related services: all services, digital marketing and medical translation. Market reports are listed in the market research section above.
Let’s discuss your priorities
Tell us the product, the market and the deadline. We will reply within one business day with a first view of the route to market.